NCT04711486View on ClinicalTrials.gov

Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

January 13, 2022

Study Completion Date

January 13, 2022

Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
DRUG

Contraloid acetate

Oral administration of drug substance capsules

DRUG

Placebo

Oral administration of placebo without any exipients.

Trial Locations (1)

10117

Charité University Medicine, Berlin

All Listed Sponsors
collaborator

Berlin Institute of Health

OTHER

collaborator

Federal Agency for Disruptive Innovation - SPRIN-D

UNKNOWN

lead

Charite University, Berlin, Germany

OTHER

NCT04711486 - Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease | Biotech Hunter | Biotech Hunter